Depemokimab is a follow-up to GSK's Nucala (mepolizumab), a once-monthly IL-5 inhibitor approved for severe asthma, CRSwNP, ...

Blue Cross Blue Shield company Health Care Service Corporation is limiting access for in-office administration of asthma ...

The European Commission has approved two new delivery formats for Nucala (mepolizumab) – a pre-filled pen injector and a pre-filled safety syringe – that will allow patients with eosinophilic ...

The China National Medical Products Administration (NMPA) has approved GSK’s Nucala (mepolizumab) as an add-on treatment with intranasal corticosteroids to treat chronic rhinosinusitis with nasal ...

GSK announced that its monoclonal antibody, Nucala (mepolizumab), has been approved ... indication for mepolizumab in China and offers patients a non-surgical treatment alternative to systemic ...

Of four treatment response measures recorded at 6 months of mepolizumab treatment, an Asthma Control Questionnaire score was ...

GSK plc announced that the China National Medical Products Administration (NMPA) has approved Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), as an add-on therapy with ...

GSK (GSK) announced that the China National Medical Products Administration has approved Nucala, a monoclonal ... for the treatment of adult patients with chronic rhinosinusitis with nasal polyps ...

Nucala was approved as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with CRSwNP for whom therapy with systemic corticosteroids and/or surgery do not ...

GSK Plc was up as the China National Medical Products Administration approved the drugmaker’s Nucala (mepolizumab) as an add-on therapy for the treatment of adult patients with chronic rhinosinusitis.

Patients should stop treatment if hepatic injury ... UPDATED: Friday, Jan. 3 at 2:45 p.m. ET GSK’s IL-5 inhibitor Nucala scored a nod in China to treat people with inadequately controlled ...